Sio Gene Therapies (Sio Gene Therapies) Capex-to-Operating-Income : 0.00 (As of Dec. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Sio Gene Therapies Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Sio Gene Therapies's Capital Expenditure for the three months ended in Dec. 2022 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2022 was $-4.48 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Sio Gene Therapies Capex-to-Operating-Income Historical Data

The historical data trend for Sio Gene Therapies's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sio Gene Therapies Capex-to-Operating-Income Chart

Sio Gene Therapies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Capex-to-Operating-Income

Get a 7-Day Free Trial

Sio Gene Therapies Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sio Gene Therapies's Capex-to-Operating-Income

For the Biotechnology subindustry, Sio Gene Therapies's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sio Gene Therapies's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Sio Gene Therapies's Capex-to-Operating-Income falls into.

Sio Gene Therapies Capex-to-Operating-Income Calculation

Sio Gene Therapies's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.695)	/	-71.562
	=	N/A

Sio Gene Therapies's Capex-to-Operating-Income for the quarter that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-4.483
	=	N/A

Sio Gene Therapies (OTCPK:SIOX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Sio Gene Therapies Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Sio Gene Therapies (Sio Gene Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

130 West 42nd Street, 26th Floor, New York, NY, USA, 10036

Website

https://www.siogtx.com

Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.

Executives

Parag V Meswani	officer: Chief Commercial Officer	130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu	officer: Chief Executive Officer	C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif	officer: Principal Financial Officer	C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo	10 percent owner	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado	10 percent owner	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc	10 percent owner	1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901